| Old Articles: <Older 4211-4220 Newer> |
 |
The Motley Fool October 8, 2007 Billy Fisher |
Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.  |
The Motley Fool October 8, 2007 Brian Lawler |
Noven's Acquisition Blues A recently acquired drug fails a late-stage clinical trial. Investors, take note.  |
The Motley Fool October 8, 2007 Billy Fisher |
McKesson Expands Its Empire A new acquisition strengthens the company's presence in the cancer drug market. Investors, take note.  |
The Motley Fool October 8, 2007 Billy Fisher |
A Menace to Big Pharma Abraxis gets tentative approval for a generic version of Pfizer's Camptosar. Many of the large-cap pharmaceutical companies are diversified to such a degree that they, like Abraxis, present interesting plays on the threat posed by generics.  |
The Motley Fool October 8, 2007 Charly Travers |
Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...  |
The Motley Fool October 8, 2007 Brian Orelli |
Pozen Submits Safety Data Will Pozen's response to its second approvable letter be enough? Investors may want to take this with a grain of salt.  |
The Motley Fool October 8, 2007 Billy Fisher |
Wheeling and Dealing at Wyeth A busy day at Wyeth. The company plans to submit a New Drug Application to the FDA, and acquires biopharmaceutical firm Haptogen.  |
The Motley Fool October 8, 2007 Brian Orelli |
New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.  |
BusinessWeek October 15, 2007 Glen Whitman |
Bad Medicine For Health Care Politicians have tried to solve America's health-care woes by enacting an individual mandate - a law requiring every adult to purchase health insurance. Despite its bipartisan support, the individual mandate is bad policy, a vain attempt to command a better result while doing nothing to achieve it.  |
The Motley Fool October 5, 2007 Brian Lawler |
OxyContin in the Crosshairs Again The state of Kentucky sues Purdue Frederick over the monetary burden that abusers of the drug OxyContin place on counties within the state.  |
| <Older 4211-4220 Newer> Return to current articles. |